Brought to you by:

Cell & Gene Therapy

pendulum silver metallic spheres on coloured background with drop shadow
Biotech

As investors pivot from cell therapy, Immatics keeps the faith

The biotech is planning for a potential commercial launch in the third quarter of 2027, a market debut Immatics intends to fund on its own.
Gabrielle Masson Jun 6, 2025 3:50am
Robert F Kennedy Jr US President Donald Trumps nominee for Secretary of Health and Human Services testifies during hi

At cell and gene roundtable, officials pledge to slash regulations

Jun 5, 2025 2:50pm
An artists depiction of DNA molecules made up of tiny particles

RegenXBio links DMD gene therapy to improved outcomes

Jun 5, 2025 8:52am
Combine

Cullinan's $700M pact for BCMA bispecific to pair with other TCE

Jun 5, 2025 4:38am
trojan horse

Ernexa's stem cell therapy shrinks ovarian tumors in mice

Jun 2, 2025 2:30pm
rainbow kite flying in the sky

ASCO: Kite's CAR-T flies high in phase 1 B-cell lymphoma study

May 31, 2025 7:00pm
More News

ASCO: Immatics cell therapy sees 56% ORR in advanced melanoma

May 31, 2025 8:00am

Intellia stock sinks on gene therapy patient's raised enzymes

May 29, 2025 9:15am

Gene editing leaders call for 10-year ban on heritable edits

May 28, 2025 7:00am

Rocket crashes as gene therapy patient dies, FDA imposes hold

May 27, 2025 9:49am